Approval · Notice of Compliance 4143 · 1997

LAMISIL: Notice of Compliance 4143

Issued August 13, 1997

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 4143
Date: August 13, 1997
Company: Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Therapeutic class: Antifungal agent

Products in this notice

Brand	DIN	Status today
LAMISIL	02031108	—
LAMISIL	02031116	Cancelled Post Market
LAMISIL	02031094	Marketed

Medicinal ingredients

TERBINAFINE HCL 125 MG per TAB
TERBINAFINE HCL 250 MG per TAB
TERBINAFINE HCL 10 MG per G